Navigation Links
ImaginAb, Inc. Announces Availability of Custom Protein Radiolabeling Services for Molecular Imaging
Date:6/7/2011

SAN ANTONIO, June 7, 2011 /PRNewswire/ -- ImaginAb, Inc. is pleased to announce the availability of custom radiolabeling services for proteins, peptides and other macromolecules as of the 1st of July 2011. This is part of the company's ongoing initiative to broaden the range of product and service offerings to the biopharma and research community and is synergistic with existing activities in custom antibody fragment engineering.

"Over the past 18 months we have grown our core antibody engineering program to over a dozen 'companion diagnostic' programs with pharmaceutical companies in addition to our own internal pipeline" commented Jenny Keppler, President and COO of ImaginAb. "In response to very high demand for our radiochemistry and, in particular our antibody labeling expertise, we have decided to make this capability a standard service offering as part of our recent LA facility expansion."

Protein/peptide labeling services will initially focus on F-18, Cu-64, I-124. Please contact sales@imaginab.com for further information and pricing.

About ImaginAb

Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.

*the technologies described in this press release are available for pre-clinical / non-human use only.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Anna Wu

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=91513


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImaginAb, Inc. and Dainippon Seiki (DNS) Co., Ltd. Conclude Technology Development Agreement for Automated Chemistry Systems
2. ImaginAb, Inc. and Eurogentec S.A. Collaborate to Produce Antibody Fragments in Pichia
3. ImaginAb, Inc. and GlaxoSmithKline Establish Collaboration
4. Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA
5. Ore Pharmaceutical Holdings Announces Name Change and Reverse/Forward Stock Split to be Effective June 10, 2011
6. Thoratec Announces Presentations at Upcoming Investor Conferences
7. COPAN Announces Strategic Global Distribution Partnership with Siemens
8. Grifols Announces the Appointment of Thomas Glanzmann as Chairman of its New Board of Directors for U.S. Operations
9. PDL BioPharma Announces Conversion Rate Adjustments for its Convertible Notes
10. Shenzhen Wuzhou Changlian International Trading Co. Announces Arrival of New Infrared Thermometer Series
11. Everist Genomics Announces New Data on OncoDefender™- CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... and BOSTON , ... a leading global pharmaceutical company and Paratek Pharmaceuticals, ... the development and commercialization of innovative therapies based ... 3 trials of sarecycline for the treatment of ... primary efficacy endpoints. Sarecycline is a once-daily, oral, ...
(Date:3/27/2017)... , March 27, 2017  Impax Laboratories, Inc. ... appointed Paul M. Bisaro as Impax,s President ... Company,s Board, effective March 27, 2017. Mr. Bisaro will ... as Interim President and Chief Executive Officer since December ... generic and branded pharmaceutical experience, Mr. Bisaro, 56, is ...
(Date:3/27/2017)...  PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company ... in children, today reported financial results for the ... 2016 and provided an update on its corporate ... progress during the fourth quarter of 2016 through ... safety study, and with our lead development candidate, ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... The ... supply chain professionals, will hold their first Northeast Regional AHVAP Meeting. For 2017, ... , “Increasingly, supply chain and value analysis professionals have a ‘seat at the ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... pleased to announce the launch of a months-long rebranding effort. This includes the ... , “Through focus group discussions and market research, we learned that a simple, ...
(Date:3/27/2017)... Texas (PRWEB) , ... March 27, 2017 , ... Harris ... hard of hearing, is bringing its latest products to the Deaf Seniors of America ... will have the opportunity to meet with knowledgeable ASL friendly staff from Harris Communications ...
(Date:3/24/2017)... ... 2017 , ... Vighter established its NAEMT Authorized Training Center ... Trauma Life Support (PHTLS) course scholarships to four medics assigned to the Minnesota ... cooperation with the American College of Surgeons to promote critical thinking in addressing ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study ... because it does not obey the rules Congress has directed the CBO to follow. ... the GOP reform would restore. Yet, it estimates a reduction in employer-based coverage due ...
Breaking Medicine News(10 mins):